We evaluated 41,537 patients admitted with myocardial infarction without ST elevation on the SCAAR register and who had not received IIBIIIB glycoprotein inhibitors and divided them into two groups: 31,351 patients who received heparin versus 10,186 who received bivalirudin. We adjusted baseline characteristics of the two groups using the Propensity score with the exception of<a href="https://solaci.org/en/2015/06/24/congress-item-6433/" title="Read more" >...</a>
Original title: Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes or stable ischemic heart disease: results from the Evaluation of Drug-Eluting Stents and Ischemic Events registry. Reference: Bangalore S et al. CircCardiovascInterv. 2014;Epub ahead of print. Bivalirudin compared to unfractionated heparin as monotherapy is associated with a lower risk of<a href="https://solaci.org/en/2014/05/14/n-4460/" title="Read more" >...</a>
Original title: A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial). Reference: Collet et al. Am J Cardiol. 2013; Epub ahead of print. ATOLL study analysis suggests that enoxaparin is superior to unfractionated heparin in reducing ischemic events and mortality in patients suffering ST elevation acute myocardial infarction (STEMI)<a href="https://solaci.org/en/2013/09/16/n-3613/" title="Read more" >...</a>
The initial strategy for the treatment of patients at high risk of bleeding (HBR) after percutaneous coronary intervention (PCI) has consisted of a short dual antiaggregation therapy (DAPT). Stents continue to improve, which has allowed the reduction of DAPT schemes and therefore the incidence of bleeding. However, researchers are also looking into another strategy to<a href="https://solaci.org/en/2023/11/22/stentless-strategy-in-acs-perfusion-and-drug-coated-balloons/" title="Read more" >...</a>
The empirical prescription of anticoagulants after percutaneous coronary intervention (PCI), also know as post-procedural anticoagulation (PPA), is nowadays a common practice that uses various types of medications. Despite studies like HORIZONS-AMI and EUROMAX, in which 41% of patients received PPA, and the CCC-ACS registry, where 75% of subjects received PPA after primary PCI, European and<a href="https://solaci.org/en/2023/08/30/esc-2023-anticoagulation-after-primary-pci-in-stemi-patients/" title="Read more" >...</a>
Coronary artery disease (CAD) coexists with aortic stenosis in about half the patients who suffer the latter. These patients receiving antiplatelet therapy are at a higher risk of periprocedural bleeding—one of the most frequent complications in patients who undergo transcatheter aortic valve replacement (TAVR). One way of limiting the risk for bleeding is choosing the<a href="https://solaci.org/en/2023/04/17/clinical-impact-of-coronary-artery-disease-on-results-after-tavr/" title="Read more" >...</a>
One of the challenges that transcatheter aortic valve replacement (TAVR) continues to face is percutaneous access closure with percutaneous closure systems (PCS). However, several systems have been developed, either by plug—such as the MANTA system—or by suture (SU)—such as the ProStar and ProGlide systems. Both of these have been tested in different analyses, but to<a href="https://solaci.org/en/2023/04/12/percutaneous-access-closure-in-tavr-are-devices-similar/" title="Read more" >...</a>
Event predictors in patients with plaque erosion and no stenting. A third of all acute coronary syndrome (ACS) cases are caused by plaque erosion. In the initial EROSION study, it was shown that patients with plaque erosion (as evidenced by OCT, with stenosis <70%, TIMI III flow, and asymptomatic) were stabilized without stent implantation (no<a href="https://solaci.org/en/2023/02/13/plaque-erosion-with-no-stenting-in-acute-coronary-syndrome-are-there-event-predictors-to-avoid-this-strategy/" title="Read more" >...</a>
For over a decade, TAVR has been showing great benefits, but conduction abnormalities such as RBBB and prior A-V block, continue to be one of the biggest challenges, since in different series the need for definite pacemaker implantation (PPM) varies between 17 to 30% in the large, randomized studies of self-expanding valves. Even though we<a href="https://solaci.org/en/2022/09/14/can-we-discharge-tavr-patients-the-same-day/" title="Read more" >...</a>
Pulmonary thromboembolism (PTE) is the third most frequent cardiovascular disease, with an increasing prevalence over time. The stratification of these patients is paramount to decide their therapeutic approach, since there have been high mortality rates for certain subgroups. The European Society of Cardiology, in its latest guidelines (2019), classified the severity of PTE according to<a href="https://solaci.org/en/2022/06/07/a-nod-to-catheter-guided-thrombolysis-in-pulmonary-thromboembolism/" title="Read more" >...</a>